The Predictive Significance of Various Prognostic Scoring Systems on the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer Patients: A Retrospective Study

The Predictive Significance of Various Prognostic Scoring Systems on the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer Patients: A Retrospective Study

ABSTRACT Background and Aims To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems—Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)—in non‐small cell lung cancer (NSCLC) patients treated with imm...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianying Liu, Jinzhan Chen, Congyi Xie, Haiyan Chen, Shuwen Yang, Hongni Jiang, Yijiao Xu
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Health Science Reports
Subjects:
Gustave Roussy Immune Score
immune checkpoint inhibitors
Lung Immune Prognostic Index
modified Glasgow Prognostic Score
non‐small cell lung cancer
prognostic analysis
Online Access:https://doi.org/10.1002/hsr2.70713
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background and Aims To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems—Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)—in non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods We conducted a retrospective analysis of clinical data from 219 NSCLC patients treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University from June 1, 2019 to January 31, 2024. The therapeutic efficacy and predictive capabilities of the scoring systems were assessed using Kaplan–Meier curves, Cox proportional hazards models, time‐dependent ROC curves, and random survival forest models. Results The median follow‐up was 29 months (IQR: 25.96–32.04), resulting in 93 observed deaths. Both LIPI and GRIm scores correlated with declining overall survival (OS) and progression‐free survival (PFS) as risk levels increased. LIPI demonstrated superior predictive performance at 12, 24, and 36 months (AUC: 0.70, 0.62, 0.61, respectively). Multivariate analysis identified immune‐related adverse events (irAEs) and lactate dehydrogenase (LDH) levels as independent prognostic factors for OS. Conclusion LIPI serves as an effective prognostic tool for NSCLC patients receiving immunotherapy, outperforming individual inflammatory markers. Additionally, irAEs and LDH levels are significant independent prognostic factors for OS.
ISSN:2398-8835

Similar Items